Here are the 8-K filings from Vogenx Inc (VOGX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow VOGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOGX filings page.
Vogenx, Inc. (VOGX) reported a third-quarter 2026 net loss of $4,907,603, compared with $284,407 in the same quarter of 2025, and operating expenses of $1,782,736. At September 30, 2026, the company reported $82.1 million in total cash, cash equivalents and marketable securities. It completed a $93.4 million IPO in August, issuing 7,187,500 shares at $13.00 per share and receiving approximately $84.4 million in net proceeds.
In October, Vogenx initiated EMERGE, a Phase 2b study of mizagliflozin for post-bariatric hypoglycemia; topline results are expected in the second half of 2027. The company plans to initiate a Phase 2 gastroparesis study in the first half of 2027. Its stated risks include material weaknesses in internal control over financial reporting.
Vogenx, Inc. announced that Richard Gorman will become Chief Commercial Officer effective October 12, 2026, and resign from the Board and all committees he served on, including Audit, Compensation, and Nominating and Corporate Governance. Gorman has served as an independent director since 2022. The company said his resignation was not the result of a disagreement over its operations, policies, or practices, and that it will search for a new independent director.
In the newly created role, Gorman will lead commercial operations and corporate strategy, including market development for post-bariatric hypoglycemia and gastroparesis, portfolio planning, and initially business development, partnering, and licensing strategy.
Vogenx, Inc. (VOGX), a clinical-stage biopharmaceutical company focused on serious metabolic and gastrointestinal diseases, has appointed Ken Toombs to its Board as a Class II independent director, effective September 21, 2026, with a term running until the 2028 annual meeting of stockholders. He will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees and act as Chair of the Audit Committee. The Board also named Peter Pieraccini as Chair of the Compensation Committee. Toombs brings roughly three decades of global professional services and life sciences-related leadership, including roles as Chief Executive Officer of PA Consulting and senior positions at Infosys Consulting, Capgemini Consulting, PricewaterhouseCoopers and IBM. Vogenx is developing its lead candidate, mizagliflozin, an investigational SGLT1 inhibitor, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing’s Syndrome, supported by clinical data from more than 500 subjects across 10 studies.
Vogenx, Inc. (VOGX) reports that JonesTrading Institutional Services LLC fully exercised its 45‑day over‑allotment option related to Vogenx’s recent initial public offering. The option covered 937,500 additional shares of common stock at a public offering price of $13.00 per share, closing on August 19, 2026 and generating additional gross proceeds of approximately $12,187,500 before underwriting discounts, commissions and expenses. Including these shares, a total of 7,187,500 shares have been issued and sold in the offering, for aggregate gross proceeds of approximately $93,437,500.